Mettler-Toledo International, I
MTD
Positions held
Your positionsMTD isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Mettler-Toledo operates in the growing diagnostics and research sector, which is essential for advancing healthcare technologies and improving patient outcomes.
- In Q2 2026, Mettler-Toledo reported a revenue increase of 8% compared to the previous quarter, reaching $1.0 billion.
- The company achieved a gross margin of 63.3% in Q2 2026, up from 58.7% in Q1 2026.
- Despite strong revenue growth, Mettler-Toledo's high trailing P/E ratio of 34.55 may indicate overvaluation in a competitive market.
- The company's debt-to-equity ratio stands at an extremely high 16,668.45, suggesting potential financial risk.
- Mettler-Toledo's operating margin, while improved, was 30.6% in Q2 2026, which may not be sustainable in a fluctuating market.
Fundamentals
| Market cap | $30.65B | Enterprise value | $32.73B | Trailing P/E | 34.47 | Forward P/E | 29.55 |
| PEG | 2.85 | Price / book | 2,389.78 | Beta | 1.19 | Dividend yield | 0.00% |
| Revenue growth | 4.5% | Earnings growth | 18.3% | Gross margin | 60.3% | Operating margin | 31.2% |
| Profit margin | 21.9% | ROE | — | ROA | 21.1% | Debt / equity | 166.68 |
| Current ratio | 1.12 | Free cash flow | $693.59M | Analyst recommendation | hold | Mean target | $1,494.08 |
| 52w high | $1,585.72 | 52w low | $1,023.05 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.0B | $947M | $1.1B | $1.0B | $983M |
| Op margin | 30.6% | 23.9% | 30.4% | 28.2% | 27.0% |
| Net income | $233M | $169M | $286M | $217M | $202M |
| Gross margin | 63.3% | 58.7% | 59.8% | 59.2% | 59.0% |
| Gross profit | $650M | $556M | $675M | $609M | $580M |
| Operating income | $314M | $227M | $343M | $290M | $266M |
- Revenue +8% vs prior quarter ($1.0B vs $947M).
- Gross margin 63.3% (was 58.7% prior quarter).
- Operating margin expanded to 30.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $4.0B | $3.9B | $3.8B | $3.9B |
| Op margin | 27.8% | 29.1% | 28.5% | 28.7% |
| Net income | $869M | $863M | $789M | $873M |
| Gross margin | 59.4% | 60.1% | 59.2% | 58.9% |
| Gross profit | $2.4B | $2.3B | $2.2B | $2.3B |
| Operating income | $1.1B | $1.1B | $1.1B | $1.1B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Mettler-Toledo (MTD): AI-Driven Pharma R&D Productivity Catalyzes Growth
2026-10-08 · Baird Adjusts Price Target on Mettler-Toledo International to $1,608 From $1,460
2026-10-07 · Evercore ISI Adjusts Price Target on Mettler-Toledo International to $1,550 From $1,350
2026-10-06 · Barclays Adjusts Price Target on Mettler-Toledo International to $1,700 From $1,575, Maintains Overweight Rating
2026-09-28 · Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus
2026-09-27 · Mettler Toledo International (MTD), Why Is It Getting Fresh Attention?
2026-09-22 · 1 S&P 500 Stock Worth Your Attention and 2 We Ignore
2026-09-21 · Goldman Sachs Adjusts PT on Mettler-Toledo International to $1,510 From $1,440, Keeps Neutral Rating
2026-09-16 · What Makes Mettler-Toledo International (MTD) an Attractive Bet?
2026-09-15 · 2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds
2026-09-14 · Is Mettler-Toledo Stock Underperforming the Nasdaq?
2026-09-10 · Research Tools & Consumables Stocks Q2 Teardown: Mettler-Toledo (NYSE:MTD) Vs The Rest
Price (daily)
Full chart · RSI · MACD · patterns